Results 11 to 20 of about 5,062,336 (201)

Radioiodine therapy versus antithyroid medications for Graves' disease [PDF]

Cochrane Database of Systematic Reviews, 2016
Chao Ma, Jiawei Xie, Hui Wang, Jinsong Li, Suyun Chen   +4 more
openalex   +2 more sources

Incidentally Detected Metachronous Malignancy in Patients of Papillary Carcinoma of Thyroid Posthigh-Dose Radioiodine Therapy. [PDF]

Indian J Nucl Med, 2023
Mishra A, Singh V, Khandelwal Y, Smitha AM, Kavali DJP, Barai S.   +5 more
europepmc   +2 more sources

Correlation among ocular surface disease, xerostomia, and nasal symptoms in patients with differentiated thyroid carcinoma subjected to radioiodine therapy: A prospective comparative study

Head and Neck, 2017
Fabrício Lopes da Fonseca, Patricia Kazue Yamanaka, Luciana Mazoti, Lica Arakawa‐Sugueno, Juliana Mika Kato, Suzana Matayoshi   +5 more
openalex   +2 more sources

Combination of targeted multikinase inhibitor and radioiodine: a new strategy of treatment for advanced differentiated thyroid carcinoma [PDF]

Waike lilun yu shijian, 2023
Advanced differentiated thyroid carcinoma (ADTC) lacks effective treatment options, and has a poor prognosis, which is an urgent clinical problem to be resolved.
LIU Wei
doaj   +1 more source

Outcome of radioiodine therapy for feline hyperthyroidism: Fixed dose versus individualized dose based on a clinical scoring system [PDF]

Open Veterinary Journal, 2022
Background: Hyperthyroidism is the most frequent endocrinopathy in older cats. To date, there is no consensus on how to best calculate the dose of radioiodine to administer to hyperthyroid cats.
Joana Matos, Bérénice Lutz, Lisa-Maria Grandt, Felix Meneses, Daniela Schweizer-Gorgas, Thierry Francey, Miguel Campos   +6 more
doaj   +1 more source

Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy.

Drug resistance updates, 2023
Thyroid cancer is the most prevalent endocrine tumor and its incidence is fast-growing worldwide in recent years. Differentiated thyroid cancer (DTC) is the most common pathological subtype which is typically curable with surgery and Radioactive iodine ...
Yu-jia Liu, Jiafeng Wang, Xiaoping Hu, Z. Pan, Tong Xu, Jiajie Xu, Liehao Jiang, Ping Huang, Yiwen Zhang, Minghua Ge   +9 more
semanticscholar   +1 more source

2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?

European Thyroid Journal, 2021
Modern use of post-operative radioactive iodine (RAI) treatment for differentiated thyroid cancer (DTC) should be implemented in line with patients’ risk stratification.
F. Pacini, D. Fuhrer, R. Elisei, D. Handkiewicz-Junak, S. Leboulleux, M. Luster, M. Schlumberger, J. Smit   +7 more
semanticscholar   +1 more source

Redifferentiation-facilitated radioiodine therapy in thyroid cancer.

Endocrine-Related Cancer, 2021
Based on experimental data, the inhibition of the MAPkinase pathway in patients with radioiodine refractory thyroid cancer was capable to induce a redifferentiation.
L. Lamartina, N. Anizan, C. Dupuy, S. Leboulleux, M. Schlumberger   +4 more
semanticscholar   +1 more source

The RAI-6 Questionnaire: A New Screening Questionnaire to Monitor Complications of Radioiodine Treatment

Frontiers in Surgery, 2021
Objective: The aim of this study is to develop a simple and efficient screening questionnaire to be able to routinely monitor potential radioiodine therapy-induced complications.Materials and Methods: A new radioiodine 6 (RAI-6) questionnaire containing ...
Samanta Buchholzer, Sethu Thakachy Subha, Livia Tchérémissinoff, Franciscus Boselie, Frédéric Triponez, Frédéric Faure, Jean-Michel Lopez, Urs Borner, Tobias Kleinjung, Jörg D. Seebach, Pavel Dulguerov, Francis Marchal   +11 more
doaj   +1 more source

NTRK- and RET-fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake.

Journal of Clinical Investigation, 2021
BACKGROUND Molecular characterization in pediatric papillary thyroid cancer (PTC), distinct from adult PTC, is important for developing molecular targeted therapies for progressive 131I-refractory PTC.
Y. Lee, Hyunjung Lee, Sun-Wha Im, Young Shin Song, D. Oh, H. Kang, J. Won, K. Jung, D. Kwon, E. Chung, J. Hah, J. Paeng, Ji-hoon Kim, Jaeyong Choi, O. Kim, J. Oh, B. Ahn, L. Wirth, C. Shin, Jong-Il Kim, Y. J. Park   +20 more
semanticscholar   +1 more source